This includes genes that may: decrease uptake of doxorubicin (SLC22A15), enhance efflux of doxorubicin (ABCC1, ABCG2, ABCD3, ABCA1), enhance conversion of doxorubicin to doxorubicinol (AKR1B10, AKR1B1), doxorubicin deoxyaglycone or doxorubicin semiquinone (NQO1), and inhibit the ability of doxorubicin to damage tumour cells through the generation of reactive oxygen species (CAT). The gene discussed is ABCA1; the disease is neoplasm.